Pfizer Dodges Challenge to Its Board
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. | Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan.
Dr. Albert Bourla is also troubled by this ... “It’s a great, great honor, which I accept on behalf of everyone at Pfizer,” said Bourla. In its announcement, the Foundation highlighted ...
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...
(JTA) — Albert Bourla, the chief executive officer of Pfizer, was named the winner of the 2022 Genesis Prize, the award sometimes called the “Jewish Nobel,” and pledged his winnings to ...
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback